Dermatology and Others

07/04/2025

Psychotropic Drugs in Dermatology Part 1: Anti-depressants and Mood Stabilisers

Link :

https://journals.lww.com/ijd/fulltext/2025/01000/psychotropic_drugs_in_dermatology_part_1_.5.aspx

Psychotropic Drugs in Dermatology. Part 2: Antipsychotics, Sedative-Hypnotics and Anxiolytics in Dermatology

Link :

https://journals.lww.com/ijd/fulltext/2025/03000/psychotropic_drugs_in_dermatology__part_2_.5.aspx

07/04/2025

Role of Polyethylene Glycol in Dermatology

Link :

https://journals.lww.com/idoj/fulltext/2025/03000/role_of_polyethylene_glycol_in_dermatology.3.aspx

07/04/2025

22/2025 (1315)

💡BOTULINUM FOR ERYTHEMA IN ROSACEA: Erythematotelangiectatic rosacea (ETR) lacks a gold-standard treatment. This study aims to evaluate the efficacy and tolerability of intradermal Botulinum Toxin-A (BoNT-A) in patients with ETR. In this randomized, double-blind, split-face study, 30 patients were enrolled. One side of the face received 15 units of BoNT-A, reconstituted in 10 mL of saline, while the control side received saline injections. Assessments were made at baseline and 1-month posttreatment. The BoNT-A-treated side demonstrated significant reductions in erythema, while no significant changes were observed on the saline control side. No serious adverse events requiring hospitalization were reported. Intradermal BoNT-A effectively reduces erythema and vascular density in patients with ETR and is well-tolerated.

Source:
Dermatol Surg. 2024 Dec 16. http://doi.org/10.1097/DSS.0000000000004528.
Effects of Botulinum Toxin Type A Treatment on Clinical and Biophysical Parameters in Patients With Erythematotelangiectatic Rosacea: A Prospective,
Randomized, Controlled, Double-Blind Study.
Dağtaş BB, Erdem O, Güneç Tİ, Avcı EB, Manav V, Koku Aksu AE.

14/03/2025

Updated Physician’s Guide to the Off-label Uses of Oral Isotretinoin

Link :

https://pmc.ncbi.nlm.nih.gov/articles/PMC3990537/

13/03/2025

Glutathione as a skin-lightening agent and in melasma: a systematic review

Link :

https://pubmed.ncbi.nlm.nih.gov/39444151/ #:~:text=Five%20randomized%20controlled%20trials%20and%20a%20single,oral%20glutathione%20was%20superior%20to%20monotherapy%20alone.

Hyperpigmentary disorders, including melasma, are challenging to treat. Glutathione has anti-melanogenic and antioxidant properties, which led to its use as a skin-lightening agent. Our objective was to review the published evidence and literature on the efficacy and safety of glutathione as a skin-...

13/03/2025

Melatonin in Dermatologic Allergic Diseases and Other Skin Conditions: Current Trends and Reports

Link :

https://pmc.ncbi.nlm.nih.gov/articles/PMC9967801/ #:~:text=It%20has%20been%20observed%20that,prevention%20of%20aging%20%5B3%5D.

08/03/2025

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)

Link :

https://pmc.ncbi.nlm.nih.gov/articles/PMC7496083/

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)

Link :

https://pmc.ncbi.nlm.nih.gov/articles/PMC7496856/

01/03/2025

LOW-DOSE ORAL MINOXIDIL DOES NOT SIGNIFICANTLY AFFECT BLOOD PRESSURE:

Minoxidil, traditionally used as an antihypertensive, is now widely used for treating various forms of alopecia due to its vasodilatory effects. While topical minoxidil has been the standard treatment, low-dose oral minoxidil (LDOM) is emerging as an effective alternative.

15/2025 (1308)

💡LOW-DOSE ORAL MINOXIDIL DOES NOT SIGNIFICANTLY AFFECT BLOOD PRESSURE: Minoxidil, traditionally used as an antihypertensive, is now widely used for treating various forms of alopecia due to its vasodilatory effects. While topical minoxidil has been the standard treatment, low-dose oral minoxidil (LDOM) is emerging as an effective alternative. This study investigates LDOM's potential hypotensive effects: LDOM did not significantly alter systolic blood pressure (MD: -0.13, 95% CI: -2.67-2.41) or diastolic blood pressure (MD: -1.25, 95% CI: -3.21-0.71). Though MAP was not significantly altered, there was a strong tendency toward decreased MAP (MD: -1.92, 95% CI: -4.00-0.17). There was a significant increase in heart rate (MD: 2.67, 95% CI: 0.34-5.01). Hypotensive symptoms were reported in 119 patients (5.0%), but no hypotensive episodes were observed. Hypertrichosis was the most frequent side effect, leading to 34.6% of discontinuations. To coclude, LDOM appears to be a safe treatment for alopecia with no significant impact on blood pressure.

Source:
J Am Acad Dermatol. 2024 Nov 7:S0190-9622(24)03100-1. doi: 10.1016/j.jaad.2024.10.057.
Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis.
Chen M, Weichert M, Guo W, Ruzic R, Briley J.

27/02/2025

Drugs for migraine prophylaxis ...

23/02/2025

Navigating Effective Therapeutic Strategies for Dermatophytosis

Link :

https://jyoungpharm.org/8420/

Extensive dermatophytosis is a fungal infection that affects more than 10% of the body's surface area. It's a severe form of dermatophytosis, a common fungal infection that affects the skin, hair, and nails.

Recalcitrant dermatophytosis refers to the relapse, recurrence, reinfection, persistence, and possibly microbiological resistance of dermatophytosis.

Factors implicated in recalcitrant dermatophytosis include the following5:

Host-fungal immune response (Th1/17 being protective and Th2 causing chronicity of infection)

Virulence potential of the infecting strain or species

Clinical type of dermatophytosis

Barrier defects

Local factors (e.g., heat, humidity, sweating, and type of clothing)

Pharmacological factors (e.g., quality of the drug, patient adherence to treatment, pharmacokinetics, and absorption of the drug)

Reinfection from other sources

18/02/2025

Sclerodermalike syndromes: Great imitators

Link :

https://www.sciencedirect.com/science/article/abs/pii/S0738081X19301865

Sclerodermalike syndromes (SLSs) comprise of a heterogeneous group of hereditary disorders with either skin thickening (eg, stiff skin syndrome) or atrophy and tightening (eg, acrogeria) can also imitate classic systemic sclerosis (SSc).

It includes :

Diseases with mucin deposition (eg, scleromyxedema, scleredema)

Disease with eosinophilia (eg, eosinophilic fasciitis)

Disease with metabolic or biochemical abnormalities (eg, nephrogenic systemic fibrosis)

Disease with endocrine disorders (eg, POEMS syndrome, or polyneuropathy, organomegaly, endocrinopathy, monoclonal lymphoproliferative disorder, and hypothyroidism)

Chronic graft-versus-host disease

Inherited progeria syndromes with early aging (eg, Werner syndrome)

In addition, SLSs can be provoked by several drugs, chemicals, or even physical injury (eg, trauma, vibration stress, radiation).

In SLSs, the distribution of skin involvement seems to be atypical compared with SSc. The acral skin involvement is usually missing, and lack of Raynaud phenomenon, scleroderma-specific antinuclear antibodies, the absence of scleroderma capillary pattern, and internal organ manifestations indicate the presence of an SLS.

Skin involvement is sometimes nodular, and the underlying tissues can also be affected. For the differential diagnosis, a skin biopsy of the deeper layers including fascia and muscle is required.

Histology does not always allow differentiation between SSc and SLSs; therefore, the diagnosis is often based on the distribution, quality of cutaneous involvement, and other accompanying clinical features.

Sclerodermalike syndromes (SLSs) comprise diseases with mucin deposition (eg, scleromyxedema, scleredema), with eosinophilia (eg, eosinophilic fasciit…

18/02/2025

Acute and recurrent pustulosis: consolidating uncommon cases of follicular pustulosis induced by UV light and other triggers

Link :

https://pmc.ncbi.nlm.nih.gov/articles/PMC10371314/

Acute and recurrent pustulosis (ARP) is an episodic eruption of pustules overlying an erythematous base with neutrophilic infiltrate that occurs and remits without treatment usually within a week. This pustular reaction can be triggered by ultraviolet (UV) light, heat, viral infection, or occur idiopathically.